US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

45.85

+0.04000.09%

Volume:2.26M

Turnover:103.46M

Market Cap:14.02B

PE:20.56

High:46.35

Open:45.85

Low:45.40

Close:45.81

52wk High:55.49

52wk Low:45.40

Shares:305.78M

Float Shares:305.78M

Volume Ratio:2.22

T/O Rate:0.74%

Dividend:2.06

Dividend Rate:4.49%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.54

PE(LYR):18.60

Loading ...

Overview Company News Filings

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

National Bank Remains a Hold on Emera (EMA)

Emera upgraded to Buy from Sell at Veritas

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

Emera, Canadian Utilities Agree to CA$72 Billion Merger

MT Newswires Live

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Emera Raises Quarterly Dividend at CA$0.74 a Share From CA$0.7325

MT Newswires Live

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update

Fastest megawatt is the winning megawatt: Tan See Leng

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Top 4 S-REITs Raising DPU by 10% or More

The Smart Investor

Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs

The Smart Investor

Dozens of Patients Take Legal Action Against Maker of Semaglutide

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances

MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/EMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.85,"timestamp":1791489600000,"preClose":45.81,"halted":0,"volume":2256527,"delay":0,"changeRate":0.0008731717965509528,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"10-09 05:33:38 EDT","open":45.85,"high":46.35,"low":45.4,"amount":103457730.53625101,"amplitude":0.020738,"askPrice":46.24,"askSize":23,"bidPrice":45.14,"bidSize":10,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":45.85,"dividendRate":0.044901,"postHourTrading":{"tag":"盘后","latestPrice":45.85,"preClose":45.85,"latestTime":"19:30 EDT","volume":1119037,"amount":51326168.544014,"timestamp":1791502204763,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.2169582855490853,"impliedVol":0.3497,"impliedVolPercentile":0.88},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":2.2169582855490853,"shares":305783111,"dividePrice":2.0587,"high":46.35,"amplitude":0.020738,"preClose":45.81,"low":45.4,"week52Low":45.4,"pbRate":"1.54","psRate":"2.23","week52High":55.49,"institutionHeld":0,"latestPrice":45.85,"committee":-0.393939,"eps":2.229761,"divideRate":0.044901,"volume":2256527,"delay":0,"ttmEps":2.229761,"open":45.85,"prevYearClose":49.24,"prevWeekClose":48.03,"prevMonthClose":47.83,"prevQuarterClose":47.83,"fiveDayClose":47.67,"twentyDayClose":49.48,"sixtyDayClose":54.15,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-10-07","current":20.562742,"percent":0.283186,"low":16.637027,"twenty":18.01228,"median":20.219873,"eighty":21.000312,"high":22.07626,"avg":19.840163,"sd":1.440407,"marketCap":14284514568.21},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36},{"date":"2026-09-25","current":19.941415,"twenty":17.94243,"median":20.238018,"eighty":21.011747,"marketCap":14658867103.01},{"date":"2026-10-02","current":20.032985,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"marketCap":14620461610.8},{"date":"2026-10-07","current":19.586954,"twenty":18.01228,"median":20.219873,"eighty":21.000312,"marketCap":14284514568.21}],"updateTime":1791525091830},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674885692","title":"Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885692","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885692?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:35","pubTimestamp":1791498900,"startTime":"0","endTime":"0","summary":"Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377767/0/en/phase-3-study-results-highlighting-deucrictibant-s-rapid-and-sustained-efficacy-in-treating-hae-attacks-published-in-the-lancet.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001440.SGD","EMA","LU0417517546.SGD","LU0106261612.USD","IE00B19Z6F94.USD","MAA","BK4215","BK4585","IE00B64QTZ34.USD","LU0256863902.USD","LU0012050646.USD","LU1169590202.USD","LU1169589451.USD","IR","BK4198","LU0256863811.USD","LU1978683503.SGD","LU0205193047.USD","LU0124384867.USD","BK4588","SPRE","BK4081","BK4161","LU0205194284.USD","IE0034390439.USD","IE00BLDYK493.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000541","title":"National Bank Remains a Hold on Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000541?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490526,"startTime":"0","endTime":"0","summary":"In a report released today, from National Bank maintained a Hold rating on Emera, with a price target of C$74.00. Emera has an analyst consensus of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/national-bank-remains-a-hold-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/national-bank-remains-a-hold-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","NBHC","BK4211","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017772","title":"Emera upgraded to Buy from Sell at Veritas","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017772?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:20","pubTimestamp":1791400812,"startTime":"0","endTime":"0","summary":"Veritas analyst Benjamin Butler upgraded Emera (EMA) to Buy from Sell with a price target of C$75, up from C$65. Published first on TheFly – the ul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-upgraded-to-buy-from-sell-at-veritas-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-upgraded-to-buy-from-sell-at-veritas-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063189","title":"BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673063189?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:01","pubTimestamp":1791316860,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Oct.  06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\"BridgeBio\" or the \"Company\"), a commercial-stage, multi-product biopharmaceutical company focused on devel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375979/0/en/bridgebio-to-present-new-acoramidis-data-including-independent-comparative-real-world-ehr-data-at-the-hfsa-annual-scientific-meeting-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASM","EMA","BK4081","BK4188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055911","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055911","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055911?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:30","pubTimestamp":1791286200,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic opt","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375352/0/en/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-oral-infigratinib-for-children-with-achondroplasia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","SPRE","BK4585","BK4081","EMA","LABU","BK4588","MAA","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053053","title":"Emera, Canadian Utilities Agree to CA$72 Billion Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053053?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:09","pubTimestamp":1791284994,"startTime":"0","endTime":"0","summary":"Emera  said Tuesday it agreed to merge with Canadian Utilities in an all-share transaction valued at approximately 14.3 billion Canadian Dollars , creating a utility and energy infrastructure company with a pro forma enterprise value of about CA$72 billion.The combined company is expected to have approximately CA$45 billion in rate base and serve roughly 6 million customers across Canada, the US, and international markets, it said.Emera shareholders are expected to own about 60% of the combined company, while former Canadian Utilities and ATCO shareholders will collectively own about 40%, the companies said.The deal is expected to close in H2 2027.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","EMA.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704062","title":"BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704062?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:30","pubTimestamp":1791199800,"startTime":"0","endTime":"0","summary":"- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374437/0/en/bbp-418-demonstrates-potential-to-be-disease-modifying-therapy-restoring-cardiac-and-disease-markers-to-unaffected-levels.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746505","title":"Emera Raises Quarterly Dividend at CA$0.74 a Share From CA$0.7325","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746505","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746505?lang=en_us&edition=fundamental","pubTime":"2026-10-03 03:16","pubTimestamp":1790968560,"startTime":"0","endTime":"0","summary":"Price: 47.86, Change: +0.19, Percent Change: +0.40","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672792573","title":"Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672792573","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672792573?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:00","pubTimestamp":1790920800,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland, Oct.  02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373510/20739/en/ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene-therapy-for-mps-iiia-sanfilippo-synd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","MAA","SPRE","EPV","BK4585","MDCO","EMA","BK4081","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671245482","title":"Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671245482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671245482?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:00","pubTimestamp":1790697600,"startTime":"0","endTime":"0","summary":"--  In September 2026, following the re-examination procedure, the. CHMP maintained its negative opinion on the Conditional Marketing. --  Feedback received through a Type C interaction with the U.S.Food and Drug Administration  contributes to the preparation. of PHOENIX as a proposed registrational Phase 3 trial and provides. a framework for finalizing the protocol and progressing U.S.H1 2025, mostly driven by the impact of the Clinigen Licensing Agreement. as of January 1, 2026, while patient demand in the Early Access Program. --  Cash runway now estimated to extend to December 2026 based on the. authorizations have been given under the Early Access Program in 14. --  In March 2026, at the European Society for Blood and Marrow. results from the ARES trial evaluating MaaT013  in aGvHD.The Company also presented CHRONOS real-world data, reporting 29%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MET","BK4211","BK4099","EMA","TM","03160","BK4215","BK4232","LU1989772923.USD","BK4588","LU1291159041.SGD","LU1496350502.SGD","BK4585","BK4081","BK4555","IND","EBMT","LU1989771016.USD","BK4604","MAA","R","BK4162","SPRE","BK4022","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671694042","title":"Fastest megawatt is the winning megawatt: Tan See Leng","url":"https://stock-news.laohu8.com/highlight/detail?id=2671694042","media":"Lin Daoyi","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671694042?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:00","pubTimestamp":1790542800,"startTime":"0","endTime":"0","summary":"\"Singapore's peak electricity demand is projected to grow at a faster pace in the coming years, driven by advanced manufacturing, digital economy and transport electrification.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/energy/fastest-megawatt-winning-megawatt-tan-see-leng?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/energy/fastest-megawatt-winning-megawatt-tan-see-leng?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["EMA","BESS","BK4081","BK4182"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461514","title":"MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461514","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461514?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244000,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368112/7767/en/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-portion-of-the-phase-2b-3-combat-als-trial-of-mn-166-ibudilast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","LU2111349929.HKD","LU0557290698.USD","LU1244550577.SGD","LU2357305700.SGD","LU1162221912.USD","IDNA","LU0106261372.USD","LU1720051017.SGD","LU1720051108.HKD","IE00BKVL7J92.USD","BMED","LU0225283273.USD","LU2023251221.USD","LU0234570918.USD","GDOC","NVIB","LU0795875169.SGD","MNOV","ARDS","LU0210528500.USD","BK4581","LU2133065610.SGD","LU0912757837.SGD","LU0882574139.USD","LU1989772840.SGD","LU0795875086.SGD","LU2264538146.SGD","LU0158827781.USD","LU0320765646.SGD","LU0106831901.USD","LU0006306889.USD","BK4588","LU0528227936.USD","LU1988902786.USD","IE00B3S45H60.SGD","CAFS","HYLG","KBWB","LU0053666078.USD","LU2089283258.USD","BK4504","LU1363072403.SGD","LU0314104364.USD","BK4516","LU0971096721.USD","LU1732800096.USD","EMA","IAI","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669562483","title":"Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening","url":"https://stock-news.laohu8.com/highlight/detail?id=2669562483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669562483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:47","pubTimestamp":1790164020,"startTime":"0","endTime":"0","summary":"- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367401/0/en/acoramidis-demonstrates-real-world-benefit-versus-tafamidis-in-attr-cm-reducing-risk-of-clinical-worsening.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATTR","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669745011","title":"Top 4 S-REITs Raising DPU by 10% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2669745011","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669745011?lang=en_us&edition=fundamental","pubTime":"2026-09-23 11:30","pubTimestamp":1790134200,"startTime":"0","endTime":"0","summary":"Four S-REITs raised DPU by 10% or more in 1H2026, but investors should examine what is driving each increase and whether it can last.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/03/Parkway-life-REIT-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/03/Parkway-life-REIT-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/top-4-s-reits-raising-dpu-by-10-or-more/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/top-4-s-reits-raising-dpu-by-10-or-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["SRT.SI","RNTY","CRPU.SI","EMA","RJMG","URE","BK7129","GLS.SI","JJJ.SI","BK6014","IVRA","XHOA","TS0U.SI","BK4139","BK4127","BK6512","8C8U.SI","BK6137","TRUR","BK6134","BK4007","BK6142","CFA","SRU.SI","BK6131","MDIV","DPU","DFRA","BPRE","CFA.SI","BK6108","BK4081","CLR.SI","BK6072","EMA.AU","IQRA","C2PU.SI","GRI","PSCF","AJBU.SI","YLDW","REIT","BK6011","RIET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669196097","title":"Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669196097","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669196097?lang=en_us&edition=fundamental","pubTime":"2026-09-22 07:30","pubTimestamp":1790033400,"startTime":"0","endTime":"0","summary":"Three S-REITs beyond the blue chips raised DPU in 1H2026, but investors should assess whether these higher distributions can continue.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/Sasseur-REITHefei-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/Sasseur-REITHefei-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/forget-banks-3-s-reits-surprising-unitholders-with-higher-dpus/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/forget-banks-3-s-reits-surprising-unitholders-with-higher-dpus/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BPRE","BK6142","BK7129","MDIV","BK4139","SRT.SI","BK6072","DPU","DFRA","GRI","CFA.SI","IQRA","BK4081","BK6512","YLDW","BK6011","BK4127","BK6137","ODBU.SI","XHOA","TRUR","CRPU.SI","PSCF","JJJ.SI","REIT","8C8U.SI","URE","CLR.SI","RNTY","IVRA","CFA","RIET","RJMG","EMA","BK4007","EMA.AU","TS0U.SI","SRU.SI","GLS.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191567475","title":"Dozens of Patients Take Legal Action Against Maker of Semaglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=1191567475","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191567475?lang=en_us&edition=fundamental","pubTime":"2026-09-20 15:41","pubTimestamp":1789890089,"startTime":"0","endTime":"0","summary":"Renowned for its role in managing type 2 diabetes and aiding weight control, the blockbuster weight-loss medication semaglutide has seen robust sales worldwide, yet its potential side effects are...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AOA","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668924809","title":"Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668924809","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668924809?lang=en_us&edition=fundamental","pubTime":"2026-09-18 22:51","pubTimestamp":1789743060,"startTime":"0","endTime":"0","summary":"If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroidsRecommendation based on","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/18/3364794/0/en/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-pmr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4202","CHMP","BK4201","PMR","BK4081","EC","AS","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667626074","title":"Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2667626074","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667626074?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:46","pubTimestamp":1789490810,"startTime":"0","endTime":"0","summary":"Aelis Farma SA ( ($FR:AELIS) ) has provided an update. In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aelis-farma-secures-key-ema-backing-and-extends-cash-runway-as-cb1-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aelis-farma-secures-key-ema-backing-and-extends-cash-runway-as-cb1-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667611371","title":"MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2667611371","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667611371?lang=en_us&edition=fundamental","pubTime":"2026-09-15 14:20","pubTimestamp":1789453234,"startTime":"0","endTime":"0","summary":"MaaT Pharma ( ($FR:MAAT) ) has issued an update. MaaT Pharma announced that the European Medicines Agency’s CHMP has signaled a negative trend in i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maat-pharma-faces-ema-setback-on-microbiome-therapy-for-agvhd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maat-pharma-faces-ema-setback-on-microbiome-therapy-for-agvhd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666585879","title":"Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666585879","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666585879?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940800,"startTime":"0","endTime":"0","summary":"- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events St","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358343/0/en/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with-achondroplasia-in-the-phase-3-propel-3-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4081","BK4156","BK4167","BK4585","BK4588","SPRE","BK4215","MAA","AHI","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}